Bio-Techne Corporation
TECHNASDAQHealthcare● Active
$52.65
+$0.66(+1.27%)
Market Cap$8.2B
P/E Ratio—
52W High$72.16
52W Low$43.2
Bio-Techne Corporation (TECH) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TECH · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.07B | $0.17B | $0.29B | $0.26B | $0.14B |
| Depreciation & Amort. | $0.11B | $0.11B | $0.11B | $0.10B | $0.09B |
| Stock-Based Comp. | $0.04B | $0.04B | $0.04B | $0.04B | $0.05B |
| Change in Working Capital | $0.01B | ($0.01B) | ($0.09B) | ($0.07B) | $0.03B |
| Net Cash from Operations | $0.29B | $0.30B | $0.25B | $0.33B | $0.35B |
| Investing Activities | |||||
| Capital Expenditure | ($0.03B) | ($0.06B) | ($0.04B) | ($0.04B) | ($0.04B) |
| Purchases of Investments | ($0.01B) | ($0.01B) | ($0.02B) | ($0.03B) | ($0.04B) |
| Sales of Investments | $0.00B | $0.03B | $0.11B | $0.03B | $0.07B |
| Net Cash from Investing | ($0.04B) | ($0.20B) | ($0.27B) | ($0.10B) | ($0.24B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.28B) | ($0.08B) | ($0.02B) | ($0.16B) | ($0.04B) |
| Dividends Paid | ($0.05B) | ($0.05B) | ($0.05B) | ($0.05B) | ($0.05B) |
| Debt Issued / Repaid | $0.03B | ($0.03B) | $0.09B | ($0.09B) | ($0.02B) |
| Net Cash from Financing | ($0.25B) | ($0.12B) | $0.02B | ($0.24B) | ($0.06B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.26B | $0.24B | $0.22B | $0.28B | $0.31B |
| FCF Margin %(computed) | 21.03% | 20.37% | 19.02% | 25.36% | 33.07% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Bio-Techne Corporation data
About Bio-Techne Corporation (TECH) Cash Flow Statement
Bio-Techne Corporation generated operating cash flow of $0.29B and free cash flow of $0.26B for 2025 — a FCF margin of 21.03%. Capital expenditure was ($0.03B).
Frequently asked questions
TECH · 4 questionsBio-Techne Corporation generated free cash flow of $0.26B for 2025, up 8.7% year-over-year.
TECH free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10